vidarabine has been researched along with Fungemia in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Non, LR; Pande, A; Romee, R; Santos, CA | 1 |
Ajana, F; Ettahar, N; Legout, L; Massongo, M; Patoz, P; Rose, C; Senneville, E | 1 |
Chim, CS; Liang, R; Wong, SS; Yuen, KY | 1 |
2 review(s) available for vidarabine and Fungemia
Article | Year |
---|---|
Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cryptococcus; Cytarabine; Dermatomycoses; Echinocandins; Exanthema; Fever; Fungemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Male; Micafungin; Opportunistic Infections; Retrospective Studies; Saccharomyces; Salvage Therapy; Trichosporon; Ustilaginales; Vidarabine; Voriconazole; Yeasts | 2017 |
[Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cutaneous Fistula; Cyclophosphamide; Diabetes Mellitus, Type 2; Female; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Osteolysis; Osteomyelitis; Rituximab; Vidarabine | 2013 |
1 other study(ies) available for vidarabine and Fungemia
Article | Year |
---|---|
Cryptococcal infection associated with fludarabine therapy.
Topics: Antineoplastic Agents; CD4-CD8 Ratio; Cryptococcosis; Fatal Outcome; Fungemia; Humans; Immunocompromised Host; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2000 |